Untitled

Tenenbaum, Alexander; Fisman, Enrique Z.; Motro, Michael

doi:10.1186/1475-2840-2-4

Cited by 78 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PPAR-α activation by fenofibrate improves insulin sensitivity and decreases thrombosis and vascular inflammation [15]. Dual PPAR alpha/gamma agonists (under development) hold considerable promise for improving the management of type 2 diabetes and providing an effective therapeutic option for treating the multifactorial components of CVD and MetS.…”

Section: Resultsmentioning

confidence: 99%

Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications

Purushothaman¹,

Badimón²,

Zias³

et al. 2006

CMM

View full text Add to dashboard Cite

Metabolic syndrome is characterized by the clustering of a number of metabolic abnormalities in the presence of underlying insulin resistance with a strong association with diabetes and cardiovascular disease morbidity and mortality. The disorder is defined in different ways, but the pathophysiology is attributable to insulin resistance. An increased release of free fatty acids (FFAs) from adipocytes block insulin signal transduction pathway, induce endothelial dysfunction due to increased reactive oxygen species (ROS) generation and oxidative stress. Dyslipidemia, associated with high levels of triglycerides and low concentrations of high density lipoproteins (HDLs), contributes to a proinflammatory state. Inflammation, the key pathogenic component of atherosclerosis, promotes thrombosis, a process that underlies acute coronary event and stroke. Tissue factor, a potent trigger of the coagulation cascade, is increased in diabetes with poor glycemic control. Therapeutic lifestyle changes (weight loss and physical activity) along with pharmacological interventions are recommended to prevent the complications of metabolic syndrome. In addition to statins, metformin, blood pressure lowering medications, interventions to increase HDLs are other important approaches to decrease the risk of cardiovascular disease. Furthermore, the peroxisome proliferator activated receptor (PPAR)-alpha and gamma agonists are potent anti-inflammatory and anti-atherogenic agents that could both improve insulin sensitivity and the long-term cardiovascular risk. In this review we focus on the molecular and pathophysiological basis of metabolic syndrome, which augments diabetes (insulin resistance) and the contribution of neovascularization in the plaque progression in diabetes, leading to rupture and coronary thrombosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications

Purushothaman¹,

Badimón²,

Zias³

et al. 2006

CMM

View full text Add to dashboard Cite

show abstract

“…GGT and ALT chould be used to predict the deposition of fat in liver cells and, therefore, indicating a change in visceral fat [ 28 ]. Changes in visceral fat were achieved through inactivation of PPAR, then followed by MetS, insulin resistance, atherosclerosis and other cardiovascular [ 29 , 30 ]. Previous epidemiological studies [ 20 , 27 , 31 – 42 ] have also suggested that liver enzymes showed high sensitivity to metabolic disorders, and liver enzymes as a diagnostic tool for the MetS is also very important, although using small sample size.…”

Section: Discussionmentioning

confidence: 99%

Liver enzymes and metabolic syndrome: a large-scale case-control study

Zhang

Jiang

et al. 2015

Oncotarget

View full text Add to dashboard Cite

Previous studies suggested that elevated liver enzymes could be used as potential novel biomarkers of Metabolic syndrome (MetS) and its clinical outcomes, although the results were inconsistent and the conclusions were underpowered. A case-control study with 6,268 MetS subjects and 6,330 frequency-matched healthy controls was conducted to systematically evaluated levels of four liver enzymes (ALT, AST, GGT and ALP), both in overall populations and in subjects with normal liver enzymes, with MetS risk using both quartiles and continuous unit of liver enzymes. We found significant associations were detected for all above analyses. Compared with quartile 1 (Q1), other quartiles have significant higher MetS risk, with ORs ranging from 1.15 to 18.15. The highest effected was detected for GGT, for which the OR value for the highest versus lowest quartile was 18.15 (95% CI: 15.7-20.9). Mutual adjustment proved the independence of the relations for all four liver enzymes. Sensitivity analyses didn't materially changed the trend. To the best of our knowledge, this study should be the largest, which aimed at evaluating the association between liver enzymes measures and MetS risk. The results can better support that liver enzyme levels could be used as clinical predictors of MetS.

show abstract

“…L’Hb A1C n’avait pas influencé l’existence d’un SM. Cependant, un diabète déséquilibré est associé à un risque accru d’un SM selon la littérature [ 22 ]. D’où la nécessité d’optimiser toujours l’équilibre glycémique de ces patients.…”

Section: Discussionunclassified

Prévalence du syndrome métabolique et des facteurs de risque cardiovasculaire chez les diabétiques de type 2 vu au service d´endocrinologie, Antananarivo

Raharinavalona¹,

Razanamparany²,

Raherison³

et al. 2020

Pan Afr Med J

View full text Add to dashboard Cite

Le syndrome métabolique (SM), étant considéré comme un facteur de risque cardiovasculaire, constitue un problème majeur de santé publique. Il aggrave les risques déjà élevés chez les diabétiques. Notre étude vise à déterminer les prévalences du syndrome métabolique et des autres facteurs de risque cardiovasculaire (FDR CV) associés chez les diabétiques de type 2. Il s’agit d’une étude transversale descriptive et analytique, menée au sein du Service d’Endocrinologie du Centre Hospitalier Universitaire Befelatanana, Antananarivo, sur une période de 7 mois. Le diagnostic du SM était posé selon les critères du consensus d'harmonisation de l’ International Diabetes Federation (2009). Nous avons retenu au total 219 patients diabétiques de type 2 dont 189 avaient présenté un SM donnant une prévalence de 86,30%. Leur âge moyen était de 58,58 ans avec une prédominance féminine (55,88%). Leur diabète évoluait, en moyenne, depuis 4,36 ans. A part l’hyperglycémie, l’hypertension artérielle était la composante du SM la plus observée, suivi de l’hypoHDLémie, de l’obésité abdominale et l’hypertriglycéridémie chez les deux genres. Les autres FDR CV associés au diabète le plus observé étaient la dyslipidémie, suivie de la surcharge pondérale ou l’obésité, de l’albuminurie et du tabagisme. Seul le surpoids ou l’obésité était le FDR CV corrélé significativement avec le SM. La prévalence du SM était très élevée chez nos diabétiques de type 2 qui cumulaient plusieurs autres FDR CV. Une prise en charge adéquate de ces différents FDR sera donc nécessaire pour réduire le SM et ses conséquences afin d’améliorer leur survie.

show abstract

Untitled

Cited by 78 publications

References 27 publications

Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications

Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications

Liver enzymes and metabolic syndrome: a large-scale case-control study

Prévalence du syndrome métabolique et des facteurs de risque cardiovasculaire chez les diabétiques de type 2 vu au service d´endocrinologie, Antananarivo

Contact Info

Product

Resources

About